→ Israel’s Teva is reportedly taking a hard look at a foreigner for its next CEO, sparking a patriotic row.
→ The FDA has approved Vertex’s Kalydeco for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. As a result, the Boston biotech bumped up its revenue projections for the year to $770 million.
→ Cinfa Biotech says its second trial for a biosimilar of Amgen’s Neulasta was positive, hitting primary and secondary endpoints.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 24,000+ biopharma pros who read Endpoints News by email every day.Free Subscription